Actively Recruiting
A Prospective, Multi-center, Cohort Study in Newly Diagnosed Marginal Zone B-cell Lymphoma
Led by Fudan University · Updated on 2025-11-19
2500
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Marginal zone lymphoma (MZL) is a type of lymphoma that can develop in the spleen, lymph nodes, and mucosal lymphoid tissues, with its occurrence increasing with age. This research aims to describe the clinical features, diagnosis, treatment status, disease progression, and main outcomes of various MZL subtypes, including mucosa-associated lymphoid tissue (MALT) lymphoma, spleen MZL, lymph node MZL, primary cutaneous MZL, and pediatric NMZL. The study also observes the safety and effectiveness of different treatments currently used for these subtypes. Participants diagnosed with MZL within the past 6 months and who have not received prior anti-tumor therapy will be enrolled. They will receive the best available treatment or follow-up based on their disease characteristics, as determined by their healthcare provider. The study does not specify a fixed treatment plan but follows patients over time to monitor their response and progression. During the study, researchers will collect medical histories, biological samples such as blood and tumor tissue, and oncology data. They will track progression-free survival for up to 10 years and assess other outcomes like time to treatment, overall survival, adverse events, and rates of disease transformation or second tumors. Participants will be followed long-term with regular evaluations to understand their disease course and treatment effects.
CONDITIONS
Brief Title
A Cohort Study in Newly Diagnosed MZL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, male or female
- Newly diagnosed marginal zone lymphoma confirmed by histopathology within the past 6 months
- No prior anti-tumor therapy, including chemotherapy, radiotherapy, biological therapy, or immunotherapy
- Willing to provide required biological samples such as blood and tumor tissue
- Voluntarily agree to join the study and sign informed consent
- Willing to participate in long-term follow-up
You will not qualify if you...
- Infection with HIV
- Inability to attend regular hospital follow-up visits
- Presence of significant comorbidities or speech impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants who undergo routine care are observed and measurements are collected before and after routine healthcare. This includes collecting medical history information, biological samples, and oncology data according to the study protocol.
Regular follow-up visits as determined by routine care and study protocol
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
R
Rong Tao, M.D
Y
Yizhen Liu, M.D., Ph.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here